keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial

keyword
https://www.readbyqxmd.com/read/28229968/cytotoxic-and-toxicogenomic-effects-of-silibinin-in-bladder-cancer-cells-with-different-tp53-status
#1
Daiane Teixeira DE Oliveira, Andre Luiz Ventura Savio, Joao Paulo DE Castro Marcondes, Tatiane Martins Barros, Ludmila Correia Barbosa, Daisy Maria Favero Salvadori, Glenda Nicioli DA Silva
Silibinin is a natural phenol found in the seeds of the milk thistle plant. Recent data have shown its effectiveness for preventing/treating bladder tumours. Therefore, in this study we investigated the cytotoxic and toxicogenetic activity of silibinin in bladder cancer cells with different TP53 statuses. Two bladder urothelial carcinoma cell lines were used: RT4 (wild-type TP53 gene) and T24 (mutated TP53 gene). Cell proliferation, clonogenic survival, apoptosis rates, genotoxicity and relative expression profile of FRAP/mTOR, FGFR3, AKT2 and DNMT1 genes and of miR100 and miR203 were evaluated...
March 2017: Journal of Biosciences
https://www.readbyqxmd.com/read/28229212/the-effect-of-a-cyclic-uniaxial-strain-on-urinary-bladder-cells
#2
Dorien Tiemessen, Paul de Jonge, Willeke Daamen, Wout Feitz, Paul Geutjes, Egbert Oosterwijk
PURPOSE: Pre-conditioning of a cell seeded construct may improve the functional outcome of a tissue engineered construct for augmentation cystoplasty. The precise effects of mechanical stimulation on urinary bladder cells in vitro are not clear. In this study we investigate the effect of a cyclic uniaxial strain culture on urinary bladder cells which were seeded on a type I collagen scaffold. METHODS: Isolated porcine smooth muscle cells or urothelial cells were seeded on a type I collagen scaffolds and cultured under static and dynamic conditions...
February 23, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28228726/current-diagnosis-and-management-of-immune-related-adverse-events-iraes-induced-by-immune-checkpoint-inhibitor-therapy
#3
REVIEW
Vivek Kumar, Neha Chaudhary, Mohit Garg, Charalampos S Floudas, Parita Soni, Abhinav B Chandra
The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agents like tremelimumab and atezolimumab for use in patients with advanced stage mesothelioma and urothelial carcinoma respectively. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as immune-related adverse events (irAEs). The spectrum of irAEs has expanded beyond more common manifestations such as dermatological, gastrointestinal and endocrine effects to rarer presentations involving nervous, hematopoietic and urinary systems...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28228601/loss-of-tumor-suppressor-kdm6a-amplifies-prc2-regulated-transcriptional-repression-in-bladder-cancer-and-can-be-targeted-through-inhibition-of-ezh2
#4
Lian Dee Ler, Sujoy Ghosh, Xiaoran Chai, Aye Aye Thike, Hong Lee Heng, Ee Yan Siew, Sucharita Dey, Liang Kai Koh, Jing Quan Lim, Weng Khong Lim, Swe Swe Myint, Jia Liang Loh, Pauline Ong, Xin Xiu Sam, Dachuan Huang, Tony Lim, Puay Hoon Tan, Sanjanaa Nagarajan, Christopher Wai Sam Cheng, Henry Ho, Lay Guat Ng, John Yuen, Po-Hung Lin, Cheng-Keng Chuang, Ying-Hsu Chang, Wen-Hui Weng, Steven G Rozen, Patrick Tan, Caretha L Creasy, See-Tong Pang, Michael T McCabe, Song Ling Poon, Bin Tean Teh
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown. About 70% of KDM6A mutations resulted in a total loss of expression and a consequent loss of demethylase function in this cancer type...
February 22, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28228557/surfactant-protein-a-inhibits-growth-and-adherence-of-uropathogenic-escherichia-coli-to-protect-the-bladder-from-infection
#5
Jiro Hashimoto, Motoko Takahashi, Atsushi Saito, Masaki Murata, Yuichiro Kurimura, Chiaki Nishitani, Rina Takamiya, Yasuaki Uehara, Yoshihiro Hasegawa, Yoshiki Hiyama, Norimasa Sawada, Satoshi Takahashi, Naoya Masumori, Yoshio Kuroki, Shigeru Ariki
Surfactant protein A (SP-A) is a multifunctional host defense collectin that was first identified as a component of pulmonary surfactant. Although SP-A is also expressed in various tissues, including the urinary tract, its innate immune functions in nonpulmonary tissues are poorly understood. In this study, we demonstrated that adherence of uropathogenic Escherichia coli (UPEC) to the bladder was enhanced in SP-A-deficient mice, which suggests that SP-A plays an important role in innate immunity against UPEC...
February 22, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28225635/role-of-imaging-in-the-local-staging-of-urothelial-carcinoma-of-the-bladder
#6
Chau Hung Lee, Cher Heng Tan, Silvana de Castro Faria, Vikas Kundra
OBJECTIVE: The purpose of this article is to review imaging modalities used in local staging of bladder urothelial carcinoma. CONCLUSION: Urothelial carcinoma is the most common histologic subtype of bladder cancer, and accurate local staging of this tumor is crucial for management. Traditionally, local staging relied on biopsy. With increasing accuracy of imaging modalities and techniques, imaging also plays an important role in the multidisciplinary care of patients with this disease...
February 22, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28225151/cytopathologic-differential-diagnosis-of-low-grade-urothelial-carcinoma-and-reactive-urothelial-proliferation-in-bladder-washings-a-logistic-regression-analysis
#7
Ebru Cakir, Ulku Kucuk, Emel Ebru Pala, Ozlem Sezer, Rahmi Gokhan Ekin, Ozgur Cakmak
Conventional cytomorphologic assessment is the first step to establish an accurate diagnosis in urinary cytology. In cytologic preparations, the separation of low-grade urothelial carcinoma (LGUC) from reactive urothelial proliferation (RUP) can be exceedingly difficult. The bladder washing cytologies of 32 LGUC and 29 RUP were reviewed. The cytologic slides were examined for the presence or absence of the 28 cytologic features. The cytologic criteria showing statistical significance in LGUC were increased numbers of monotonous single (non-umbrella) cells, three-dimensional cellular papillary clusters without fibrovascular cores, irregular bordered clusters, atypical single cells, irregular nuclear overlap, cytoplasmic homogeneity, increased N/C ratio, pleomorphism, nuclear border irregularity, nuclear eccentricity, elongated nuclei, and hyperchromasia (p ˂ 0...
February 22, 2017: APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica
https://www.readbyqxmd.com/read/28221692/gastrointestinal-recurrent-urothelial-cancer-of-the-remnant-ureter-invading-the-ileal-conduit-pet-ct-imaging
#8
M Hafertepe, B D Nguyen
No abstract text is available yet for this article.
February 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28218662/microrna-expression-profile-identifies-high-grade-non-muscle-invasive-bladder-tumors-at-elevated-risk-to-progress-to-an-invasive-phenotype
#9
Sara M Lenherr, Sheaumei Tsai, Brasil Silva Neto, Travis B Sullivan, Cara B Cimmino, Tanya Logvinenko, Jason Gee, Wei Huang, John A Libertino, Ian C Summerhayes, Kimberly M Rieger-Christ
The objective of this study was to identify a panel of microRNAs (miRNAs) differentially expressed in high-grade non-muscle invasive (NMI; TaG3-T1G3) urothelial carcinoma that progress to muscle-invasive disease compared to those that remain non-muscle invasive, whether recurrence happens or not. Eighty-nine high-grade NMI urothelial carcinoma lesions were identified and total RNA was extracted from paraffin-embedded tissue. Patients were categorized as either having a non-muscle invasive lesion with no evidence of progression over a 3-year period or as having a similar lesion showing progression to muscle invasion over the same period...
February 17, 2017: Genes
https://www.readbyqxmd.com/read/28217761/modeling-of-chronic-radiation-induced-cystitis-in-mice
#10
Bernadette M M Zwaans, Sarah Krueger, Sarah N Bartolone, Michael B Chancellor, Brian Marples, Laura E Lamb
PURPOSE: Radiation cystitis (RC), a severe inflammatory bladder condition, develops as a side-effect of pelvic radiation therapy in cancer patients. There are currently no effective therapies to treat RC, in part due to the lack of preclinical model systems. In this study, we developed a mouse model for RC and used a small animal radiation research platform (SARRP) to simulate the targeted delivery of radiation as used with human patients. METHODS AND MATERIALS: To induce RC, C3H mice received a single radiation dose of 20Gy delivered through two beams...
October 2016: Advances in Radiation Oncology
https://www.readbyqxmd.com/read/28217699/the-female-urinary-microbiota-urinary-health-and-common-urinary-disorders
#11
REVIEW
Linda Brubaker, Alan J Wolfe
This review provides the clinical context and updated information regarding the female urinary microbiota (FUM), a resident microbial community within the female bladder of many adult women. Microbial communities have variability and distinct characteristics in health, as well as during community disruption (dysbiosis). Information concerning characteristics of the FUM in health and disease is emerging. Sufficient data confirms that the microbes that compose the FUM are not contaminants and are cultivatable under appropriate conditions...
January 2017: Annals of Translational Medicine
https://www.readbyqxmd.com/read/28216943/non-transitional-cell-carcinoma-of-the-upper-urinary-tract-a-case-series-among-305-cases-at-a-tertiary-urology-institute
#12
Mohamed Mohamed Elawdy, Diaa-Eldin Taha, Yasser Osman, Mohamed Abd El-Hamid, Mohsen El-Mekresh
Non-transitional cell carcinomas (non-TCC) of the upper urinary tract as squamous cell carcinoma (SCC), adenocarcinoma, and small cell carcinoma (SmCC) are rare with few case reports in the literature. We retrospectively reviewed our patients who surgically treated for upper tract urothelial carcinoma from 1983 to 2013 for non-TCC pathological cancer characteristics and survival. Among 305 patients, only 5 (1.6%) cases were found: One case of SmCC, another had adenocarcinoma, and 3 SCC cases. None of them had intravesical recurrence and the cancer-specific survival for non-TCC cohort is markedly decreased (log-rank = 0...
January 2017: Urology Annals
https://www.readbyqxmd.com/read/28214031/the-impact-of-histological-variants-of-urothelial-carcinoma-on-clinical-outcomes-following-trimodality-bladder-sparing-chemoradiation
#13
EDITORIAL
Anne E Kiltie, Lisa Browning
No abstract text is available yet for this article.
February 14, 2017: European Urology
https://www.readbyqxmd.com/read/28212539/fluorescence-in-situ-hybridization-status-of-voided-urine-predicts-invasive-and-high-grade-upper-tract-urothelial-carcinoma
#14
Xiaohong Su, Han Hao, Xuesong Li, Zhisong He, Kan Gong, Cuijian Zhang, Lin Cai, Qian Zhang, Lin Yao, Yi Ding, Yanqing Gong, Dong Fang, Zheng Zhang, Liqun Zhou
Here, we assessed the diagnostic accuracy of fluorescence in situ hybridization (FISH) for detecting aggressive upper tract urothelial carcinoma (UTUC). A total of 210 UTUC patients from a single hospital in China were enrolled in this retrospective study between 2012 and 2016. Patients were classified as FISH-positive or -negative based on FISH analysis of voided urine, and the clinicpathological characteristics of these two patient groups were compared. Patients with positive FISH results had more advanced tumor stages and higher tumor grades than those with negative results...
February 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28212061/pd-1-and-pd-l1-inhibitors-as-salvage-therapy-for-urothelial-carcinoma
#15
Guru Sonpavde
No abstract text is available yet for this article.
February 17, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28212060/pembrolizumab-as-second-line-therapy-for-advanced-urothelial-carcinoma
#16
Joaquim Bellmunt, Ronald de Wit, David J Vaughn, Yves Fradet, Jae-Lyun Lee, Lawrence Fong, Nicholas J Vogelzang, Miguel A Climent, Daniel P Petrylak, Toni K Choueiri, Andrea Necchi, Winald Gerritsen, Howard Gurney, David I Quinn, Stéphane Culine, Cora N Sternberg, Yabing Mai, Christian H Poehlein, Rodolfo F Perini, Dean F Bajorin
Background Patients with advanced urothelial carcinoma that progresses after platinum-based chemotherapy have a poor prognosis and limited treatment options. Methods In this open-label, international, phase 3 trial, we randomly assigned 542 patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy to receive pembrolizumab (a highly selective, humanized monoclonal IgG4κ isotype antibody against programmed death 1 [PD-1]) at a dose of 200 mg every 3 weeks or the investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine...
February 17, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28210516/immunohistochemical-investigation-of-her-akt-mtor-pathway-and-cellular-adhesion-molecules-in-urothelial-carcinomas
#17
Nikolaos Koletsas, Triantafyllia Koletsa, Spyros Choidas, Konstantinos Anagnostopoulos, Stavros Touloupidis, Thomas Zaramboukas, Georgia Raptou, Nikolaos Papadopoulos, Maria Lambropoulou
Background. Several investigators have suggested the possibility that the expression of both EGFR and HER2 could be utilized for molecularly targeted therapy in urinary bladder cancer. We tried to evaluate the expression of HER2 and EGFR and activation of the AKT/PTEN/mTOR pathway in urothelial carcinomas and if there is any association between them and cellular adhesion molecules (CAMs). Materials and Methods. Forty-one paraffin-embedded urothelial cancer tissue blocks were collected. Immunostains for HER2, EGFR, MIB1, phospho-AKT, PTEN, phospho-mTOR, e-cadherin, p-cadherin, and b-catenin were performed on tissue microarrays sections...
2017: Pathology Research International
https://www.readbyqxmd.com/read/28207636/association-between-pretransplant-cancer-and-survival-in-kidney-transplant-recipients
#18
Dag Olav Dahle, Tom Grotmol, Torbjørn Leivestad, Anders Hartmann, Karsten Midtvedt, Anna V Reisæter, Geir Mjøen, Hege K Pihlstrøm, Hege Næss, Hallvard Holdaas
BACKGROUND: Kidney transplantation in recipients with a previous malignancy is often deferred 2-5 years after cancer treatment due to fear of cancer recurrence. In Norway, the required waiting period has been 1 year. METHODS: We compared patient and graft survival of recipients with pretransplant cancer to the outcomes of matched recipients without such cancer (comparators) using Cox regression. RESULTS: From 1963 to 2010, 377 of 5867 recipients (6...
February 15, 2017: Transplantation
https://www.readbyqxmd.com/read/28207504/unusual-presentation-of-direct-intraperitoneal-metastases-complicated-with-massive-ascites-from-plasmacytoid-variant-of-bladder-cancer-and-adenocarcinoma-of-colon-a-case-report-and-literature-review
#19
Yu-Hua Shao, Chien-Chang Kao, Shou-Hung Tang, Tai-Lung Cha, Chih-Wei Tsao, En Meng, Dah-Shyong Yu, Guang-Huan Sun, Sheng-Tang Wu
BACKGROUND: Plasmacytoid urothelial carcinoma (PUC) is a distinct variant of urinary bladder cancer, with a high propensity for invasion and poor prognosis. These tumors occur most commonly in male patients with the age of reported cases ranging from 46 to 87 years. CASE REPORT: We present a case of a 74-year-old male patient having massive ascites and bilateral lower leg edema. Colonoscopy showed a 3-cm lesion in the sigmoid colon and an edematous nonpapillary tumor was found by cystoscopy in the bladder...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28203296/incorporating-vegf-targeted-therapy-in-advanced-urothelial-cancer
#20
REVIEW
Sujata Narayanan, Sandy Srinivas
Patients with relapsed or refractory urothelial carcinoma (UC) have poor prognosis coupled with few options for systemic treatment. The role of angiogenesis in the evolution of cancers has been established, and studies have shown that it plays a key role in the pathogenesis of UC. Many targeted agents have been used in phase I-II trials for the treatment of UC, with encouraging but modest results. Recently, studies combining angiogenesis inhibitors with other chemotherapeutic agents were able to achieve objective responses higher than most commonly used second-line therapies in UC...
January 2017: Therapeutic Advances in Medical Oncology
keyword
keyword
4084
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"